Skip to main content
An official website of the United States government

Dordaviprone Hydrochloride

(dor-da-VIP-rone HY-droh-KLOR-ide)

This page contains brief information about dordaviprone hydrochloride and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Modeyso
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Dordaviprone hydrochloride is approved to treat:

  • Glioma (certain types) in adults and children aged 1 year and older whose cancer got worse after other therapy.

Dordaviprone hydrochloride is approved under FDA's Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that it provides a clinical benefit in these patients.

More About Dordaviprone Hydrochloride

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Dordaviprone Hydrochloride - A lay language summary of important information about this drug.

Research Results and Related Resources

Targeted Therapy to Treat Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Dordaviprone Hydrochloride - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email